Abstract
The promyelocyte (PML)-retinoic acid receptor alpha (RARalpha) fusion gene results from a t(15;17) chromosome translocation in acute promyelocytic leukaemia. We have analysed the oncogenic potential of the human fusion PML-RARalpha product in chicken using retrovirus vectors. We show that PML-RARalpha transforms very early haematopoietic progenitor cells in vitro and induces acute leukaemias. Neither PML nor RARalpha domains alone achieve such a transformation. The PML-RARalpha viruses recovered from the transformed cells carry two point mutations in the PML domain, one of which alters both the pattern of intracellular localization of the fusion protein and its functional interference with AP-1, thus defining an essential domain in PML for oncogenic transformation.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Amino Acid Sequence
-
Animals
-
Bone Marrow Cells
-
Cell Transformation, Neoplastic
-
Chickens
-
Hematopoietic Stem Cells / cytology*
-
Humans
-
Leukemia, Experimental / genetics*
-
Molecular Sequence Data
-
Neoplasm Proteins*
-
Nuclear Proteins*
-
Oncogenes*
-
Point Mutation
-
Promyelocytic Leukemia Protein
-
Receptors, Retinoic Acid / genetics*
-
Recombinant Fusion Proteins
-
Retinoic Acid Receptor alpha
-
Transcription Factors / genetics*
-
Translocation, Genetic
-
Tumor Suppressor Proteins
Substances
-
Neoplasm Proteins
-
Nuclear Proteins
-
Promyelocytic Leukemia Protein
-
RARA protein, human
-
Receptors, Retinoic Acid
-
Recombinant Fusion Proteins
-
Retinoic Acid Receptor alpha
-
Transcription Factors
-
Tumor Suppressor Proteins
-
PML protein, human